Jacobs Levy Equity Management’s Anika Therapeutics ANIK Stock Holding History

Jacobs Levy Equity Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.18M	Sell	217,530 -48,097	-18%	-$713K	0.01%	507
2026 Q1	$3.85M	Buy	265,627 +70,042	+36%	+$813K	0.02%	471
2025 Q4	$1.88M	Buy	195,585 +85,771	+78%	+$821K	0.01%	588
2025 Q3	$1.03M	Sell	109,814 -9,524	-8%	-$91K	﹤0.01%	710
2025 Q2	$1.26M	Sell	119,338 -16,941	-12%	-$214K	0.01%	714
2025 Q1	$2.05M	Buy	136,279 +17,303	+15%	+$288K	0.01%	654
2024 Q4	$1.96M	Buy	+118,976	New	+$2.35M	0.01%	592
2022 Q3	–	Sell	-16,397	Closed	-$366K	–	991
2022 Q2	$366K	Buy	+16,397	New	+$366K	﹤0.01%	903
2019 Q3	–	Sell	-9,768	Closed	-$397K	–	917
2019 Q2	$397K	Sell	9,768 -8,980	-48%	-$327K	0.01%	775
2019 Q1	$567K	Buy	+18,748	New	+$642K	0.01%	763
2014 Q1	–	Sell	-12,040	Closed	-$459K	–	888
2013 Q4	$459K	Sell	12,040 -1,200	-9%	-$37K	0.01%	726
2013 Q3	$316K	Buy	13,240 +500	+4%	+$11.2K	0.01%	784
2013 Q2	$217K	Buy	+12,740	New	+$184K	﹤0.01%	879

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Jacobs Levy Equity Management's ANIK Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Anika Therapeutics (ANIK) stake by 18% in Q2 2026, selling an estimated $713K and leaving 217,530 shares worth $3.18M. The position accounts for 0.01% of the portfolio, ranked #507.

Jacobs Levy Equity Management first reported a position in ANIK in Q2 2013 and has held it in 13 quarters since. The position peaked at $3.85M in Q1 2026. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

Jacobs Levy Equity Management held 217,530 shares of Anika Therapeutics worth $3.18M as of Q2 2026.
Jacobs Levy Equity Management sold 48,097 Anika Therapeutics shares in Q2 2026, an estimated $713K.
Anika Therapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #507 holding.
Jacobs Levy Equity Management first reported a position in Anika Therapeutics in Q2 2013 and has held it in 13 quarters since.
Jacobs Levy Equity Management's Anika Therapeutics position peaked at $3.85M in Q1 2026.
133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.